Every Canadian affected by a brain tumour has the right to have the information and support needed to fully participate in all aspects of life.

Working to change practices and policies that are not inclusive of this community is critical. Brain Tumour Foundation of Canada advocates on behalf of the brain tumour community by:

  • Investigating and advocating on important issues to the brain tumour community
  • Contributing to Canadians’ understanding about these issues and how they can work affect change
  • Working with partners in Canada, North America and Internationally on efforts important to brain tumour patients.

June 2022 Ontario Provincial Election Questions

During this provincial election campaign, we invite you to engage with provincial candidates about these issues that are of critical importance to the brain tumour community. You may find opportunities to speak with candidates in door-to-door candidacy campaigns, community gatherings, regional debates, and town hall meetings. You may also choose to write or email the candidates in your area.

We have developed the following questions that can be posed to provincial candidates. We encourage you to use these questions in your conversations.

Read The Questions Here

COVID-19 Community Survey

In the fall of 2020, Brain Tumor Foundation of Canada invited our community to participate in a survey so that we could learn more about how they were being impacted by COVID-19 and what we could do to help.

Learn More

January 2022 Position Paper – National Pharmacare in Canada

The responsibility for health care falls to the thirteen (13) provinces and territories of Canada. Each provides basic hospital and physician services in exchange for federal funding support. The services they provide under this federal agreement do not include prescription or hospital drug coverage. Each province or territory makes independent decisions on WHAT pharmaceutical drugs they fund for the public, and HOW that drug funding is accessed.

Read Our Position Paper Here

Lomustine Discontinuation Advocacy Letter and Fact Sheet

Bristol Myers Squibb (BMS) has announced their discontinuation of lomustine (CCNU), a chemotherapy drug that is often used to treat glioblastoma. Our advocacy letter to Bristol Myers Squibb outlines the potential impact that the discontinuation of lomustine may have on the brain tumour community.

Advocacy Letter Fact Sheet Updates

Advocating for Yourself

Speak up, ask questions, and always remember – your health comes first. This section is for patients and their networks to learn their rights, seek the best treatments and maximize quality of life.

Learn how to be your own best advocate

Increased Research Funding

As the leading organization in Canada focused on funding brain tumour research, we are the only group dedicated to overcoming this deadly disease.

Thanks to the support of donors, research funds are distributed every year to researchers across Canada who are examining the cause of and cure for brain tumours.

Read more about research funding here

Patients Rights in Canada

A Patient Bill of Rights lists the “basic rules of conduct between patients and medical caregivers” (CHAI, 2021).

Bills of Rights are informed by applicable healthcare laws and legislation, which vary based on geographic location.

Learn More

Equal Access to Care

Equal access to drugs that treat brain tumours and associated conditions, as well as the related financial burden, is an issue for families across Canada. Where a patient lives should never determine the treatment for a brain tumour.

Learn more about equal access across Canada

August 2020 Position Paper – Dexamethasone and Drug Shortages

On May 1, 2020, the federal government’s Tier Assignment Committee added dexamethasone to the Tier 3 list. It is an important step, but there is far more action needed. Our position paper recognizes the vital importance of pharmaceutical drug products for persons with brain tumours, including dexamethasone.

Read our position paper here

Is Temozolomide covered in your province?

Check the map